BIIB033

BIIB033 (also known as Anti-LINGO-1) is a monoclonal antibody targeting LINGO1. It is currently being developed by Biogen as a treatment for diseases such as multiple sclerosis and optic neuritis.[1][2][3]

See also

References

  1. "Biogen MS Drug Results Are 'Mildly Encouraging' In Eye Disease Test". Forbes. Retrieved 2015-10-13.
  2. "Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex". Clinical Trials. Retrieved 2015-10-13.
  3. Tran, Jonathan Q.; Rana, Jitesh; Barkhof, Frederik; Melamed, Isaac; Gevorkyan, Hakop; Wattjes, Mike P.; Jong, Remko de; Brosofsky, Kristin; Ray, Soma (2014-08-01). "Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033". Neurology - Neuroimmunology Neuroinflammation. 1 (2): e18. doi:10.1212/NXI.0000000000000018. ISSN 2332-7812. PMC 4202679Freely accessible. PMID 25340070.
This article is issued from Wikipedia - version of the 10/18/2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.